ライフサイエンスコーパス: need

1 uced dyskinesia (LID) in Parkinson disease (PD) is an unmet need.

2 he recent legal restrictions of China in distillates import need a quick and sensitive method for their quantification.

3 To facilitate development of topical therapeutics, we need an efficient model for assessing different formulations

4 An urgent need exists for adjuvant treatments that can enhance or repla

5 ity effects with meningococcal serogroup B vaccines and the need for a booster dose to sustain individual protection agai

6 e with protection against dengue virus have highlighted the need for a human DENV challenge model to better evaluate the

7 There is a need for a more refined, molecularly based classification mod

8 ply and need tool developed to anticipate future supply and need for all physician specialties.

9 e of bariatric surgery for treating NASH and underscore the need for clinical trials in this area.

10 Significant progress in meeting the need for FP has been achieved in Senegal, but more needs to b

11 tterns were encountered in 31% of patients, emphasizing the need for further evaluation in larger series and close collab

12 bio-molecular studies and cell-surface analysis without the need for labeling processes.

13 lusively by macroscopic techniques so far, there is a clear need for local-probe measurements.

14 There is a need for new greener materials (than for example polyethylene

15 showed teduglutide to increase urine production and reduce need for parenteral support volume in patients with short bow

16 ials that form photoactivated depots of insulin without the need for polymers, by linking photolysis to an isoelectric po

17 on's unique pattern of functional connectivity, without the need for pre-existing or hidden pathology.

18 ol for reducing of biomass recalcitrance and therefore, the need for pretreatments.

19 l-2-furfurylamines under biomimetic conditions, without the need for protecting groups, yielding powerful synthons in pre

20 y identifying peripheral biomarkers that will eliminate the need for scalp biopsies.

21 Experimental discovery of such solitons is hindered by the need for spatial imaging of the 3D fields, which is difficult

22 nt in treatment delay during the study period highlight the need for standardized diagnostic routines and a better follow

23 ry, mepolizumab treatment led to a greater reduction in the need for surgery and a greater improvement in symptoms than p

24 amic regulation of protein interactions in vivo, there is a need for techniques that can yield time-resolved information

25 There remains the need, however, for a soluble, versatile, HBC-based platform,

26 In particular, there is an unmet need in rapid, reliable detection of short RNA regions which

27 fferences need validation, and their impacts on disparities need more detailed investigation.

28 This need not be the case, because gestural enrichments are typica

29 h more unbalanced tumour phylogenetic trees, suggesting the need of denser sampling of tumours at relapse.

30 results in a robust and efficient workflow, as segmentation need only be performed at one cardiac phase, while wall posit

31 nts, is the notion that patients and their families may not need or want palliative care involvement early in the disease

32 ature, patents, technical reports, or the web is a pressing need shared by researchers and patent attorneys from differen

33 However, there remains a need to anticipate supply given the rapid growth of specialty

34 d breaks (DSBs) represent highly deleterious DNA damage and need to be accurately repaired.

35 Even if successful, however, these approaches will need to be combined with additional complementary approaches

36 Other factors may need to be considered in deciding the optimal approach.

37 resumed in G2-phase, indicating that specific interactions need to be dissolved for replication to proceed.

38 des in a modular architecture, have potential benefits, but need to be explored further.

39 e substantial overhead of quantum error correction, and the need to compile into discrete gate sets, the necessary comput

40 defects in signaling can lead to malignancy illustrates the need to control Notch activity tightly.

41 Therefore, there is an urgent need to develop a high-throughput and efficient strategy to i

42 There is an urgent need to develop an efficacious and affordable vaccine to cont

43 There is a need to develop efficient statistical methods and computation

44 There is a need to develop methods that are robust to platform/batch eff

45 e suggested the existence of resistance mechanisms with the need to identify predictive factors of therapy response.

46 ng an opportunity to reduce imaging time by eliminating the need to perform T1 sequences.

47 However, there is an urgent need to rigorously estimate actual mortality rates and quanti

48 The growing elderly population worldwide highlights the need to understand how aging promotes CVD in order to develop

49 udy is an adaptation of the FutureDocs physician supply and need tool developed to anticipate future supply and need for

50 These differences need validation, and their impacts on disparities need more d